Loading stock data…
TCRT
$2.52-0.11 (-4.18%)
Market ClosedLast close May 13
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alaunos Therapeutics, Inc. in the Healthcare sector is trading at $2.52. The stock is currently near its 52-week low of $1.67, remaining 13.1% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$2.52
Potential Downside
0%
Whystock Fair Value$2.52
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.49M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.13
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-193.96%
Volume
Today's trading volume
11,852
Recent News
Ziopharm: Q3 Earnings Snapshot
HOUSTON (AP) — Alaunos Therapeutics, Inc. TCRT) on Friday reported a loss of $1.2 million in its third quarter. The Houston-based company said it had a loss of 55 cents per share.
Ziopharm: Q2 Earnings Snapshot
HOUSTON (AP) — Alaunos Therapeutics, Inc. TCRT) on Thursday reported a loss of $1.1 million in its second quarter. On a per-share basis, the Houston-based company said it had a loss of 63 cents.